A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Ultra-high field proton magnetic resonance spectroscopy (1HMRS) offers a unique opportunity to measure the concentration of neurometabolites implicated in psychosis (PSY). The extant 7T 1HMRS literature measuring glutamate-associated neurometabolites in the brain in PSY in vivo is small, but a comprehensive, quantitative summary of these data can offer insight and guidance to this emerging field. This meta-analysis examines proton spectroscopy (1HMRS) measures of glutamate (Glu), glutamine (Gln), glutamate+glutamine (Glx), gamma aminobutyric acid (GABA), and glutathione (GSH) across 255 individuals with PSY (121 first episode) and 293 healthy comparison participants (HC). While all five neurometabolites were lower in PSY as compared to HC, only Glu (Cohen’s d = −0.18) and GSH (Cohen’s d = −0.21) concentrations were significantly lower in PSY, whereas concentrations of Gln, Glx, and GABA did not significantly differ between groups. Notably, 1HMRS methodological choices and sample demographic characteristics did not impact study-specific effect sizes for PSY-related Glu or GSH differences. This review thus provides further evidence of neurometabolite dysfunction in first episode and chronic PSY, and thereby suggests that Glu and GSH abnormalities may additionally play a role in more incipient stages of the disorder: in clinical high risk stages. Additional 7T neurochemical imaging studies in larger, longitudinal, and unmedicated samples and in youth at risk for developing psychosis are needed. Such studies are critical for elucidating the neurodevelopmental and clinical time course of PSY-related neurometabolite alterations, and for assessing the potential for implicated metabolites to serve as druggable targets for decreasing PSY risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Interest in elucidating the role of Glu in the pathogenesis of PSY first emerged due to findings that phencyclidine (NMDA receptor antagonist), ketamine (NMDA receptor antagonist), and Δ-9-THC (transiently disturbs Glu) have psychotomimetic properties, inducing both positive and negative symptoms similar to those seen…”
BackgroundThe Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 2×
“…identification of neural targets and corresponding interventions paramount. tra-high field glutamate, glutamine, GABA and glutathione 1HMRS in 20.06.028 There is a significant literature supporting the dopamine hypothesis of PSY, which was first proposed over 40 years ago (Howes and Kapur, 2009).”
BackgroundInfluentialSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Lower levels of brain Glumay be indicative of a lower density of glutamatergic synapses (Olney and Farber, 1995), reduced excitatory neurotransmission, and/or disrupted glutamate metabolism in PSY.”
BackgroundPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Chemical exchange saturation transfer (CEST): what is in a name and what isn't?
van Zijl, P. C. M., & Yadav, N. N. (2011) · Magnetic Resonance in Medicine · doi:10.1002/mrm.22761 · Cited by 1,155
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035 · cited 2×
“…dysfunction in PSY remain unknown, one model posits that a loss of inhibitory control due to NMDA-mediated interneuron dysfunction leads to elevated glutamate levels initially, glutamate-induced excitotoxicity, and an eventual loss of glutamatergic connections (Moghaddam and Javitt, 2012).”
BackgroundGlutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Cited by
Smucny, J., Dienel, S. J., Lewis, D. A., & Carter, C. S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01089-0 · Cited by 231
In Vivo Brain GSH: MRS Methods and Clinical Applications
Bottino, F., Lucignani, M., Napolitano, A., Dellepiane, F., Visconti, E., Rossi Espagnet, M. C., & Pasquini, L. (2021) · Antioxidants · doi:10.3390/antiox10091407 · Cited by 50
Pan, Y., Dempster, K., Jeon, P., Théberge, J., Khan, A. R., & Palaniyappan, L. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200167 · Cited by 28
Relating glutamate, conditioned, and clinical hallucinations via 1H-MR spectroscopy
Leptourgos, P., Bansal, S., Dutterer, J., Culbreth, A., Powers, A., Suthaharan, P., Kenney, J., Erickson, M., Waltz, J., Wijtenburg, S. A., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac006 · Cited by 15
Metadata
- Authors
- Sydnor, V. J., & Roalf, D. R.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 226
- Pages
- 61-69
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W3044660945
- Cited by
- 67
- References
- 33
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.